Table 2.

Anti-inflammation therapeutic strategies in hypertension.

Agents	Intervention objects	Mechanisms	Biological effects	Reference
Minocycline	A patient with resistant hypertension	Has direct effects on gut microbiota	May cause a large reduction in Firmicutes and Bacteroidetes and a corresponding dramatic increase in Proteobacteria	(139)
Mycophenolate mofetil	Ang-II induced hypertensive rat models or patients with autoimmune disease	Prevents the development of salt-sensitive hypertension	Significantly reduces tubulointerstitial injury, superoxide-producing cells and T-cell infiltration and activation	(140–142)
Anti-IL-17A antibody	Hypertension rat models or patients with psoriatic arthritis	Inhibits IL-17 receptor unit A	Blocks the transport pathway including sodium hydrogen exchanger 3, Na-K-2Cl-cotransporter, Na-Cl cotransporter, epithelial sodium channel of renal tubules stimulated or upregulated by IL-17A	(72, 85–87, 143)
Statins	Patients with intractable hypertension	Anti-inflammatory and antioxidant effects that could reduce arterial stiffening and protect vascular endothelium	Inhibits the production of ROS, reducing the circulating level of pro-inflammatory cytokines and inhibits the expression of adhesion molecules on vascular endothelial cells and smooth muscle cells	(102, 144)